Literature DB >> 25653715

CLEFT PALATE IN HIV-EXPOSED NEWBORNS OF MOTHERS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY.

Ayotunde James1, Babatunde Oluwatosin2, Georgina Njideka3, Onyekwere George Benjamin1, David Olufemi3, Robert Leo4, Isaac Folorunso5, Olusegun Olusina6.   

Abstract

AIMS: Cleft lip/palate, though rare, is the commonest head and neck congenital malformation. Both genetic and environmental factors have been implicated in the aetiopathogenesis but the role of in-utero exposure to human immunodeficiency virus (HIV) and highly active antiretroviral therapy (HAART) is still being investigated. This short communication reports the occurrence of cleft palate in three newborns exposed in-utero to HIV and HAART.
MATERIAL AND METHODS: This is a case series of HIV-exposed newborns observed to have cleft palate among a larger cohort of HIV-exposed and unexposed newborns in a study evaluating the effect of HIV infection and HAART on newborn hearing. The Risk Ratio (RR) was calculated to detect a potential association between in-utero exposure to Efavirenz containing ART and cleft palate.
RESULTS: Three HIV-exposed newborns with cleft palate were identified during hearing screening performed on 126 HIV-exposed and 121 HIV unexposed newborns. Two had exposure to tenofovir+lamivudine+efavirenz (TDF+3TC+EFV) while the third had exposure to zidovudine+lamivudine+nevirapine (ZDV+3TC+NVP) during the first trimester. There was no statistically significant association between presence of cleft palate and exposure to an EFV containing HAART regimen (p=0.07, RR=10.95 [0.94-126.84]).
CONCLUSIONS: This communication highlights the possible aetiologic role of HAART in cleft palate, the need for further prospective follow-up studies and establishment of antiretroviral pregnancy, birth and neonatal registries.

Entities:  

Keywords:  Cleft palate; efavirenz; highly active antiretroviral therapy (HAART); human immunodeficiency virus (HIV); nevirapine; newborns

Year:  2014        PMID: 25653715      PMCID: PMC4313880          DOI: 10.1111/ors.12117

Source DB:  PubMed          Journal:  Oral Surg        ISSN: 1752-2471


  27 in total

1.  Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C.

Authors:  Susan B Brogly; Mark J Abzug; D Heather Watts; Coleen K Cunningham; Paige L Williams; James Oleske; Daniel Conway; Rhoda S Sperling; Hans Spiegel; Russell B Van Dyke
Journal:  Pediatr Infect Dis J       Date:  2010-08       Impact factor: 2.129

Review 2.  Efavirenz: a review.

Authors:  Saskia M E Vrouenraets; Ferdinand W N M Wit; Jacqueline van Tongeren; Joep M A Lange
Journal:  Expert Opin Pharmacother       Date:  2007-04       Impact factor: 3.889

Review 3.  Principles and practice of teratology for the obstetrician.

Authors:  Barbra Fisher; Nancy C Rose; John C Carey
Journal:  Clin Obstet Gynecol       Date:  2008-03       Impact factor: 2.190

4.  Genetic studies in the Nigerian population implicate an MSX1 mutation in complex oral facial clefting disorders.

Authors:  A Butali; P A Mossey; W L Adeyemo; P A Jezewski; C K Onwuamah; M O Ogunlewe; V I Ugboko; O Adejuyigbe; A I Adigun; L O Abdur-Rahman; I I Onah; R A Audu; E O Idigbe; M A Mansilla; E A Dragan; A L Petrin; S A Bullard; A O Uduezue; O Akpata; A O Osaguona; H O Olasoji; T O Ligali; B M Kejeh; K R Iseh; P B Olaitan; A R Adebola; E Efunkoya; O A Adesina; O M Oluwatosin; J C Murray
Journal:  Cleft Palate Craniofac J       Date:  2011-07-08

5.  Teratogenicity of high vitamin A intake.

Authors:  K J Rothman; L L Moore; M R Singer; U S Nguyen; S Mannino; A Milunsky
Journal:  N Engl J Med       Date:  1995-11-23       Impact factor: 91.245

6.  A study of cleft lip and palate in neonates born in a large Malaysian maternity hospital over a 2-year period.

Authors:  N Y Boo; A R Arshad
Journal:  Singapore Med J       Date:  1990-02       Impact factor: 1.858

7.  Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).

Authors:  Federico Pulido; Jose R Arribas; Jose M Miró; María A Costa; Juan González; Rafael Rubio; Jose M Peña; Miguel Torralba; Montserrat Lonca; Alicia Lorenzo; Concepcion Cepeda; Juan J Vázquez; Jose M Gatell
Journal:  J Acquir Immune Defic Syndr       Date:  2004-04-01       Impact factor: 3.731

8.  Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.

Authors:  Wilbert C Jordan; Ronald Jefferson; Francis Yemofio; Laurie Tolbert; Vivian Conlon; Harlon Carroll; D Christopher Green; Aaron Green; Rachel Green
Journal:  J Natl Med Assoc       Date:  2003-12       Impact factor: 1.798

9.  Prevalence of orofacial clefts in Nigeria.

Authors:  A Butali; W L Adeyemo; P A Mossey; H O Olasoji; I I Onah; A Adebola; A Akintububo; O James; O O Adeosun; M O Ogunlewe; A L Ladeinde; B O Mofikoya; M O Adeyemi; O A Ekhaguere; C Emeka; T A Awoyale
Journal:  Cleft Palate Craniofac J       Date:  2013-04-04

10.  Efavirenz use during pregnancy and for women of child-bearing potential.

Authors:  Matthew F Chersich; Michael F Urban; Francois W D Venter; Tina Wessels; Amanda Krause; Glenda E Gray; Stanley Luchters; Dennis L Viljoen
Journal:  AIDS Res Ther       Date:  2006-04-07       Impact factor: 2.250

View more
  4 in total

1.  Molecular Diagnostics and In Utero Therapeutics for Orofacial Clefts.

Authors:  J D Oliver; E C Turner; L R Halpern; S Jia; P Schneider; R N D'Souza
Journal:  J Dent Res       Date:  2020-07-01       Impact factor: 6.116

2.  Determinants of orofacial clefting II: Effects of 5-Aza-2'-deoxycytidine on gene methylation during development of the first branchial arch.

Authors:  Ratnam S Seelan; Partha Mukhopadhyay; Dennis R Warner; Irina A Smolenkova; M Michele Pisano; Robert M Greene
Journal:  Reprod Toxicol       Date:  2016-12-05       Impact factor: 3.143

3.  The characteristics and perioperative outcomes of children with orofacial clefts managed at an academic hospital in Johannesburg, South Africa.

Authors:  Prosperity A Sithole; Palesa Motshabi-Chakane; Michel K Muteba
Journal:  BMC Pediatr       Date:  2022-04-19       Impact factor: 2.567

4.  Clinical relevance of breast and gastric cancer-associated polymorphisms as potential susceptibility markers for oral clefts in the Brazilian population.

Authors:  Renato Assis Machado; Edimilson Martins de Freitas; Sibele Nascimento de Aquino; Daniella Reis B Martelli; Mário Sérgio Oliveira Swerts; Silvia Regina de Almeida Reis; Darlene Camati Persuhn; Helenara Salvati Bertolossi Moreira; Verônica Oliveira Dias; Ricardo D Coletta; Hercílio Martelli-Júnior
Journal:  BMC Med Genet       Date:  2017-04-04       Impact factor: 2.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.